Accept All Cookies
May 11, 2020
Cadwalader Intellectual Property Group partner John Moehringer participated in a panel discussion last week at the annual policy meeting of the Global Intellectual Property committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading innovative biopharmaceutical research companies.
In light of the COVID-19 pandemic, the panel discussion – titled “Longer-term Implications: Capitalizing on Opportunities” – focused on how the industry can best position itself to showcase the value of innovation and the policy ingredients necessary to kick-start investment in the research, development, and manufacture of new treatments and vaccines.
Moehringer was joined by fellow panelists Keith Maskus, Professor of Economics at the University of Colorado; Pedram Sameni, CEO and founder of Patexia; and moderator Jon Santamauro, Senior Director at AbbVie.
Moehringer discussed the value of Artificial Intelligence (AI) and the ability of the U.S. patent system to effectively promote the investment of time and money required by AI, including the implications of the PTO’s recent Decision On Petition in the DABUS matter, finding that a machine may not be an inventor.
“We are increasingly seeing the power of AI, as many leading technology and pharmaceutical companies around the world are rising to meet the challenges created by the pandemic,” Moehringer said. “Among other lessons, what COVID-19 has taught us in the IP space is that we need to consider other rights beyond traditional patent protection, including Trade Secrets and data protection rights.”
Moehringer, a partner in Cadwalader’s Intellectual Property Group based in the firm's New York office, handles complex patent and Trade Secret litigation, primarily in the electrical engineering, computer science, telecommunications, and medical device fields. In addition to representing clients in patent infringement suits in the U.S. district courts, Moehringer also has substantial experience representing clients in the U.S. International Trade Commission.